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Abstract
Background: Familial adenomatous polyposis, an autosomal dominant inherited disease caused by germline
mutations within the APC gene, is characterized by early onset colorectal cancer as a consequence of the intrinsic
phenotypic feature of multiple colorectal adenomatic polyps. The genetic investigation of Greek adenomatous
polyposis families was performed in respects to APC and MUTYH germline mutations. Additionally, all available
published mutations were considered in order to define the APC mutation spectrum in Greece.
Methods: A cohort of 25 unrelated adenomatous polyposis families of Greek origin has been selected. Genetic
testing included direct sequencing of APC and MUTYH genes. APC gene was also checked for large genomic
rearrangements by MLPA.
Results: Analysis of the APC gene performed in a Greek cohort of twenty five FAP families revealed eighteen
different germline mutations in twenty families (80%), four of which novel. Mutations were scattered between exon
3 and codon 1503 of exon 15, while no large genomic rearrangements were identified.
Conclusion: This concise report describes the spectrum of all APC mutations identified in Greek FAP families,
including four novel mutations. It is concluded that the Greek population is characterized by genetic
heterogeneity, low incidence of genomic rearrangements in APC gene and lack of founder mutation in FAP
syndrome.
Background
The precancerous syndrome familial adenomatous poly-
posis (FAP) is transmitted as an autosomal dominant
trait and is caused by germline mutations within the
adenomatous polyposis coli (APC) gene [1,2]. FAP syn-
drome is primarily characterized by the presence of
multiple colorectal adenomatous polyps and a variable
range of extracolonic manifestations [3].
The classical FAP phenotype involves the presence of
at least 100 colorectal adenomas developed at a young
age, whereas the profuse phenotype is associated with
the presence of thousands polyps and an increased risk
of developing very early onset colorectal cancer. The
discrete location of mutations on the APC gene deter-
mines the particular FAP phenotypic manifestations, as
well as the severity of the disease [4,5]. Notably, a parti-
cular severe phenotype, involving a higher number of
polyps and an earlier onset of colorectal cancer, has
been observed in patients carrying mutations in the
most mutated codon (codon 1309) of the APC gene
[6-8], with a population frequency ranging from 0% to
29% [9]. Additionally, a study in the Balearic Island
revealed that the hotspot c.3183_3187delACAAA muta-
tion has a founder effect [10]. This study is the only
report of a founder effect in FAP syndrome, since the
APC gene is characterized by a high rate of de novo
mutations, enhancing the spectrum of mutations identi-
fied [9,11,12].
On the other hand, an attenuated form of disease,
characterized by the later onset and smaller number of
polyps, is caused by mutations on the extreme 5’ end or
the 3’ end [13] or the alternatively spliced region of
exon 9 of the gene [14-16]. In the latter case, the
mutated codon can be ruled out during the normal spli-
cing occurring in colonic mucosa, resulting in a milder
phenotype. The alternative splicing mechanism involving
exon 9, where removal of codons 312 to 412 is taking
place, produces a shorter APC isoform. Both isoforms
are present in normal tissues, the expression of which is
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Gardner syndrome, constituting a phenotypic variant
of FAP is defined by the association of colorectal poly-
posis and the clinical triad of desmoid tumours, osteo-
mas and epidermoid cysts, appears to be associated with
a classic form of FAP syndrome [17]. These patients are
characterized by high mortality rates due to obstruction
and perforation of surrounding structures within the
bowel, caused by desmoids tumours [18].
The last few years a new type of polyposis syndrome,
resembling to the attenuated form of FAP, has been
identified. The so-called MUTYH associated polyposis
syndrome (MAP), which is inherited in an autosomal
recessive manner, is caused by mutations of the base
excision repair gene MUTYH [19].
In this study the APC coding region has been analyzed
for point mutations and large deletions in 25 families
matching the FAP syndrome criteria. Eighteen different
mutations, out of which four novel, have been identified
in twenty families. APC negative families were then
checked for germline MUTYH mutations. The aim of
this study is to describe the complete APC mutation
spectrum identified in Greek FAP families and to corre-
late it to the phenotype.
Methods
Patients
FAP patients and their relatives were referred through
the Molecular Diagnostics Laboratory of N.C.S.R
Demokritos of Athens. The specific study focuses on 42
individuals from 25 families. Patients with clinical detec-
tion of colorectal polyps, ranging from 50 to 1000 ade-
nomas, were included in the study. In order for a
detailed family tree to be constructed, an interview is
taking place with as many family members as possible
and informed consent was taken from all patients before
genetic testing. The study was approved by the Bioethics
Committee of the National Centre for Scientific
Research “Demokritos” (Reference Number 240/EHΔ/
10.8) in agreement with the 1975 Helsinki statement,
revised in 1983.
DNA and RNA isolation
Total genomic DNA was isolated from peripheral blood
leukocytes following the salt extraction procedure [20].
Total RNA was extracted from blood using Trizol (Invi-
trogen, Paisley, UK) following standard protocols.
Reverse Transcription PCR
A template-primer mix containing 1000 ng of total RNA
and 60 μM of random hexamers were boiled at 65°C for
10 minutes, followed by immediate cool on ice. After
the addition of 8 mM MgCl2,1m Md N T P s ,5m M
DTT, 20 U RNase inhibitor and 10 U MMLV reverse
transcriptase (Roche Diagnostics, Mannheim, Germany)
the mixture was incubated at 50°C for 30 minutes fol-
lowed by enzyme inactivation at 85°C for 5 min. cDNA
were used for subsequent PCR amplification. Primers
used are available on request.
Mutational analysis
T h ec o m p l e t ec o d i n gs e q u e n c eo ft h eAPC gene, com-
prising of 15 exons, as well as all 16 exons of the
MUTYH gene, including splice junctions, were amplified
by Polymerase Chain Reaction. PCR conditions and pri-
m e r su s e da r ea v a i l a b l ef r o mt h ea u t h o r su p o nr e q u e s t .
PCR product purification was performed using a
vacuum driven ultrafiltration purification system, where
PCR samples are transferred to a filter plate with a
membrane resin, which retains the PCR products free
from non-incorporated nucleotides and primers
(Macherey-Nagel, Düren, Germany). Sequencing reac-
tions were performed using the v.3.1 BigDye Terminator
Cycle Sequencing kit (Applied Biosystems, Foster City,
CA) and PCR products were electrophorized on the ABI
Prism® 310 Genetic Analyzer. Sequences obtained were
aligned, using Sequencher® PC software (Gene Codes,
USA), with reference sequences from Genbank
(NM_000038) and examined for the presence of
mutations.
Multiplex ligation-dependent probe amplification (MLPA)
For the detection of large deletions or duplications of
the APC gene, Multiplex Ligation-dependent Probe
Amplification (MLPA) was carried out using the SALSA
P043 APC exon deletion test kit (MRC-Holland, Nether-
lands), following manufacturer’s instructions.
Results
In the present study 18 different APC germline mutations
have been identified in 20 out of the 25 Greek families
screened, suggesting a detection rate of 80%. Four muta-
tions are described here for the first time, to the extent of
our knowledge, whereas two de novo mutations have been
found, suggesting a 10% frequency in the studied popula-
tion. Eight mutations were nonsense, caused by a single
base substitution; one was an intronic base substitution
causing aberrant splicing, one caused aberrant splicing in
the alternatively spliced region, located in exon 9 of the
APC gene [21], while the remaining eight were either
insertions or deletions causing a frameshift and the intro-
duction of a premature stop codon. The distribution of
germline mutations identified, occurring over the 5’ half of
the APC gene, is in concert with most reports, while quite
interesting is the low frequency of the two hotspot muta-
tions (codons 1061 and 1309) identified in most popula-
tions studied. Despite the extensive analysis of all samples
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cially available MLPA kit, none was detected within our
cohort. The APC mutational spectrum, which includes the
findings of the specific study, as well as previously
reported mutations in the Greek population are summar-
ized in Figure 1, whereas all patient clinical data, family
members tested and detailed mutation information are
summarized in Table 1.
Identification and characterization of families with novel
mutations
The four novel mutations identified were scattered along
the Greek mutation spectrum characterized by this
study, with one located on exon 3, one on intron 7 and
two within exon 15. Proband 1195, who was classified
as an attenuated FAP case, was found to carry a novel
mutation (c.340delC), located on codon 114 of exon 3.
T h es p e c i f i cm u t a t i o ni sp o s s i b l yde novo,s i n c eb o t h
proband’s parents deceased at their late seventies, with
no apparent FAP clinical symptoms; no genetic material
of the parents was available.
Family 1186 is classified as a classic FAP phenotype
case, in the absence of extracolonic manifestations.
Direct sequencing of the APC gene revealed the non-
sense mutation c.2701 C > T, located on exon 15. The
proband’s mother was diagnosed with colorectal cancer
a tt h ea g eo f3 0i nt h ep r e s e n c eo fm u l t i p l ec o l o r e c t a l
polyps, while her brother, who was asymptomatic at the
age of 30, did not carry the mutation.
Another novel mutation (c.3830delT) identified in this
study involves a family (F85) characterized by the severe
form of FAP. The proband’s mother was diagnosed with
colorectal cancer and deceased at the age of 37, while
one of her sister and one of her brother proceeded in
having a total colectomy at the ages of 20 and 25,
respectively, due to the existence of thousands polyps
throughout their colon and rectum. The region encod-
ing for the essential 20-amino acid repeats, where b-
catenin binding is taking place, involves codons 1265 to
2065. Therefore the particular alteration disrupts most
20-amino acid repeats, possibly explaining the severity
of the family’s phenotype.
Figure 1 The mutational spectrum of APC germline mutations identified in 35 unrelated Greek families. Each bullet represents a carrier
family of an APC germline mutation. Black bullets represent mutations identified by our group, whereas grey bullets represent mutations
identified by others in Greek families. * [29], ° [30], ^ [31]
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1270 revealed a single base substitution located in intron
7, eight nucleotides upstream of exon 8 (c.835-8 A > G).
This change results in a 7-bases insertion, which was
detected by sequencing of the corresponding cDNA
fragment. This is taking place due to the creation of a
new AG splice acceptor site seven bases upstream the
actual site, causing a frameshift and a premature termi-
nation codon. A schematic representation is shown on
Figure 2.
Family with multiple phenotypic features
A particular aggressive phenotypic expression of the
mutation c.1263 G > A, located on exon 9, was identi-
fied in a 28-year old female patient. The proband was
diagnosed with multiple adenomatous polyps, mostly
allocated in the sigmoid and transverse colon, as well as
gastric polyps of adenoma nature at the age of 28. She
undertook a total colectomy and performed surgical
removal of gastric polyps twice, at the age of 28 and 34.
At her 34 years of age she developed a desmoid tumour
located at the mesenterium, while at her 37 was diag-
nosed with an additional desmoid tumour situated
between the endometrium and the urinary tract. It is
hypothesized that the mutation was maternally inher-
ited, since the proband’s mother and maternal uncle
deceased from generalized cancer at the age of 52 and
56, respectively and therefore, there is no available
genetic material to confirm this. The proband’sd a u g h -
ter, aged 12 years old, was tested negative for the speci-
fic mutation. This family could be possible a case of
Gardner syndrome, although the characteristic osteomas
a n de p i d e r m o i dc y s t sw e r en o tp o s s i b l et ob ev e r i f i e d
clinically, as the proband deceased soon after the genetic
diagnosis.
Genotype-Phenotype correlation
Three patients in our cohort were found to carry muta-
tions in the APC regions that have been associated with
the attenuated FAP phenotype. More specifically, the
Table 1 APC germline mutations identified in Greek FAP patients with supportive clinical data
Family
ID
Exon Mutation Consequence Age at
diagnosis
Phenotype Cancer Reason for
diagnosis
F1195 3 c.340delC p.Pro114LeufsX11 49 50-100 colorectal polyps N symptoms
F1275 4 c.520_523delCCTT p.Pro174X1 30 50-100 colorectal polyps N family member
F75 6 c.694C > T p.Arg232X 37 50-100 colorectal polyps N symptoms
F1270 8 c.835-8 A > G aberrant splicing of ex.
7
38 100-200 colorectal polyps N symptoms
F76 9 c.1234 C > T p.Gln412X & aberrant
splicing of ex. 9
30 30-50 colorectal polyps N symptoms
F1196 9 c.1263G > A p.Trp421X 28 100-1000 colorectal polyps, UGI
polyps, desmoids
Y symptoms
F113 11 c.1495C > T p.Arg499X 51 100-1000 colorectal polyps N symptoms
F741 11 c.1495C > T p.Arg499X 40 100-200 colorectal polyps N symptoms
F880 15A c.2181_2182insG p.Asn728GlufsX6 26 100-1000 colorectal polyps N family member
+symptoms
F160 15B c.2413 C > T p.Arg805X 23 100-1000 colorectal polyps,
desmoids, thyroid cancer
Y family member
F1186 15C c.2701C > T p.Gln901X 28 100-1000 colorectal polyps Y family member
+symptoms
F899 15D c.2821G > T p.Glu941X 23 50-100 colorectal polyps N family
F274 15D c.2991 T > A p.Tyr997X 56 100-1000 colorectal polyps N symptoms
F474 15D c.2991 T > A p.Tyr997X 26 100-1000 colorectal polyps N family member
F83 15E c.3183_3187delACAAA p.Gln1062FsX1 36 100-1000 colorectal polyps Y symptoms
F446 15E c.3189_3192delTGAG p.Glu1064LysfsX61 34 100-1000 colorectal polyps N family member
F71 15E c.3214delA p.Ser1072ValfsX54 35 100-1000 colorectal polyps N symptoms
F50 15E c.3260_3261delTC p.Leu1087GlnfsX31 23 100-1000 colorectal polyps N symptoms
F85 15G c.3830delT p.Leu1277TyrfsX11 28 > 1000 colorectal polyps, 150
UGI polyps
N family member
+symptoms
F153 15I c.4508C > G p.Ser1503X 48 100-200 colorectal polyps N symptoms
cDNA numbering is based on reference sequence: GenBank NM_000038. +1 corresponds to the A of the ATG translation initiation codon. Novel mutations are
highlighted in boldface.
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tively spliced region of exon 9 of APC gene. All three
patients showed the attenuated FAP phenotype, charac-
terized by low polyp burden, ranging from 30 to 100
adenomas, in the absence of exctracolonic manifesta-
tions. Moreover, none of the aforementioned patients
developed colorectal cancer.
Furthermore, twelve patients were characterized by
the classical FAP phenotype. These patients were found
to carry mutations between codons 421 to 1503. Color-
ectal cancer was diagnosed in four cases, with a mean
age at onset of 28.7 years. The number of polyps ranged
from 100 to 1000. Desmoids were reported in two
patients, while thyroid cancer has been described in one
case.
Remarkably, a relatively frequent mutation (p.R232X)
located in exon 6 of the gene, mostly associated with
the classical FAP phenotype, was identified in a patient
who was presented with an attenuated phenotype.
Moreover, three more patients carrying mutations in
gene regions associated with t h ec l a s s i cF A Pp h e n o t y p e
(F1270: intron 7, F899: exon 15 and F153: exon 15)
were presented with a medium polyp burden, ranging
from 100-200 polyps.
A patient carrying the novel mutation c.3830delT (p.
Leu1277TyrfsX11) was presented with the severe form
of FAP, characterized by profuse colorectal polyposis, as
well as upper gastrointestinal polyposis.
APC- negative families
Four out of the five APC- mutation negative patients
show an attenuated phenotype, comparably late age of
diagnosis and low polyp burden. The fifth is presented
with a number of colorectal adenomatous polyps (>
100) compatible to FAP syndrome and colorectal cancer
in two family relatives around the age of 35. All APC-
mutation negative patients have been tested for
MUTYH germline mutations. No MUTYH mutations
were identified in these families. Furthermore, no APC
deletions or rearrangements have been detected by
MLPA.
Lack of founder effect
As indicated in Figure 1, the majority of mutations iden-
tified in our cohort were unique, except for two, which
were shared between two families. Even if we combine
all available data regarding APC mutations in Greek
families, only three more mutations are recurrent (iden-
tified also in two families) in a total of thirty different
mutations. These data are consistent with the lack of a
founder effect in respects to FAP syndrome in the
Greek population.
Frequency of rearrangements and the “classic” FAP
mutations
Despite the fact that the MLPA technique has been
introduced in our series of experiments, no large rear-
rangements within the APC gene have been identified
in our cohort. Interestingly, only one such mutation
has been reported in the Greek population, suggesting
a frequency rate of 2.8%. Another interesting finding is
the frequency of the two mutational hotspots (codon
1061: c.3183_3187delACAAA and codon 1309:
c.3927_3931delAAAGA) in the Greek population. The
frequent 1061 mutation has been identified once in
our cohort (frequency rate of 2.8%), while the
Figure 2 Characterization of the intonic base substitution causing alternative splicing. (A) DNA sequence of intron 7-exon 8 boundaries,
where the AG acceptor site is highlighted in the dotted box in both the wild type and the mutant DNA and the premature termination codon
is coloured in red. (B) The 7-bp insertion upstream of exon 8 on cDNA from the patient is coloured in grey.
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Page 5 of 8c.3927_3931delAAAGA mutation located on codon
1309 has been reported twice in the total Greek muta-
tional spectrum, suggesting a frequency rate of 5.7%.
Discussion
Multiple genetic studies performed in FAP syndrome
have shown a quite clear pattern of phenotype-genotype
correlation [5,22]. This finding is consistent within our
cohort, and constitutes a great tool in the early mutation
identification and the correct clinical management of
APC mutation carriers, as well as their family relatives.
The Greek APC mutation spectrum is characterized by
heterogeneity, while it is notable that almost every FAP
family carries a different mutation. Moreover, four novel
mutations have been identified, one of which causes
attenuated FAP. One novel single base deletion
(c.3830delT), causing a frameshift and a termination
codon was found to be associated with the severe form
of FAP syndrome. This finding is in concert with
already published data, highlighting the association of
profuse polyposis to mutations located between codons
1250 and 1464 of APC [4].
An interesting case reported within our cohort is the
one carrying the Gardner’s syndrome characteristics.
Although the characteristic osteomas and epidermoid
cysts could not be confirmed on our patient, the fact
that the specific mutation, c.1263 G > A (p.W421X), has
been described in a large Spanish family with typical
Gardner’s syndrome features [23], indicate that our
family can be classified as a Gardner syndrome case.
Surprisingly, the proband in the Spanish family did not
develop desmoids tumours. Therefore, patients carrying
the exact same mutation are presented with a quite dif-
ferent phenotypic expression, which is clearly influenced
by modifier genes and/or environmental factors.
A 20% of FAP families in our study were tested nega-
tive for point mutations and rearrangements of the
entire APC coding sequence, as well as for germline
MUTYH mutations. A quite frequent cause of FAP has
been illustrated to be the allele-specific reduced APC
expression in patients with unidentified APC mutation
[24]. A restriction of this technique includes the require-
ment for patient heterozygosity in at least one nucleo-
tide polymorphism within the APC coding region.
Unfortunately, this technique could not be performed in
our patients since the genetic material (RNA) needed
was not available in a subset of patients, whereas in the
two APC-negative, where RNA was at hand, no hetero-
zygosity at coding polymorphisms has been identified.
Finally, the existence of genes, other than APC and
MUTYH, susceptible to colorectal adenomas and cancer
cannot be excluded.
The surprising findings of the specific work, which
reviews all the reported APC mutations identified within
the Greek population, is the low frequency of gene rear-
rangements, as well as the rare presence of the common
reported mutations at codons 1061 and 1309. In most
populations examined, large gene rearrangements con-
tribute to the 5% of total mutations identified [9],
whereas in specific populations, such as the Swedish,
this may rise up to 9% [25]. The Greek adenomatous
polyposis cohort, constituting of forty families in total,
s h o w saf r e q u e n c yo f2 . 8 % ,ar a t el o w e rt h a nt h e
expected. Additionally, the rate of the two highly fre-
quent mutations, c.3183_3187delACAAA and
c.3927_3931delAAAGA, in the Greek population was
found to be 2.8% and 5.7%, respectively. This is an inter-
esting finding, as these two mutations are usually found
in higher frequencies in most populations [26].
The low detection rate for the two hot spot mutations,
although rare, has been previously reported in the Gali-
cian population, where the 1061 mutation was not
detected at all and the 1309 mutation was detected in a
frequency of 5.2% [27]. Furthermore, the common
mutation at codon 1309 was not identified in a series of
Australian FAP families [28]. This observation, along
with the absence of a founder effect in APC, highlights
the mutation heterogeneity, probably caused by the high
emigration rates, within the Greek adenomatous polypo-
sis patients.
According to the literature, attenuated FAP charac-
terizes families carrying mutations on the 5’end of the
gene, the alternatively spliced region of exon 9 and the
3’ end of the gene to codon 1580. Severe FAP is asso-
ciated with mutations in codon 1309, while classic FAP
mutations span the 5’ end of exon 15. These observa-
tions are in consistency with the findings in the Greek
population, as well.
Conclusion
This study reports the APC mutation spectrum identi-
fied in Greek FAP families, including four novel muta-
tions. Furthermore, the genetic heterogeneity of the
Greek population, characterized by low incidence of
genomic rearrangements in the APC gene can be a use-
ful tool in the genetic testing available for the predictive
d i a g n o s i so fa tr i s kf a m i l ym e m b e r s ,f o l l o w e db yt h e
customized clinical management.
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